SCHEMBL23998613

SCHEMBL23998613

Fc1cccc(-c2cc3nc(Cl)ccn3n2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.41
ALDH1A1 P00352 6/20 0.41
HPGD P15428 6/20 0.41
LMNA P02545 5/20 0.41
MAPT P10636 4/20 0.41
KMT2A Q03164 4/20 0.41
L3MBTL1 Q9Y468 4/20 0.41
MEN1 O00255 3/20 0.41
HTT P42858 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
POLB P06746 2/20 0.41
MAPK1 P28482 3/20 0.41
GAA P10253 2/20 0.41
HSD17B10 Q99714 2/20 0.41
NPSR1 Q6W5P4 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
RCE1 Q9Y256 1/20 0.41
RAD52 P43351 1/20 0.40
PDE10A Q9Y233 1/20 0.40
F2RL3 Q96RI0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3348495 0.86 SMN1; SMN2 (0.46) KDM4EALDH1A1HPGDLMNAMAPT
SCHEMBL23998385 0.85 CYP19A1 (0.41) KDM4EALDH1A1HPGDLMNAMAPT
SCHEMBL25768021 0.84 FYN (0.43) KDM4EALDH1A1HPGDLMNAMAPT
SCHEMBL30375568 0.83 FYN (0.42) KDM4EALDH1A1HPGDLMNAMAPT
SCHEMBL30250682 0.82 KDM4E (0.41) KDM4EALDH1A1HPGDLMNAMAPT
SCHEMBL23998434 0.80 ALDH1A3 (0.47) ALDH1A1MAPK1HSD17B10IDO1
SCHEMBL31692752 0.77 TDP2 (0.47) KDM4EALDH1A1MAPTHSD17B10NPC1
SCHEMBL30375110 0.77 GRM5 (0.47) KDM4EALDH1A1HPGDLMNAMAPT
SCHEMBL23998500 0.75 NPC1 (0.40) MAPTL3MBTL1POLBF2RL3KDM5B
SCHEMBL23998260 0.75 KMT2A (0.45) KDM4EALDH1A1HPGDLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122010947-A Antagonists of adenosine A2a receptors 阿道尔克斯治疗有限公司 2026-05-12 CN disclosed
US-12617796-B2 Antagonists of the adenosine A2a receptor JANSSEN PHARMACEUTICA NV (BE) 2026-05-05 US disclosed
US-20230203041-A1 ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
US-20230203041-A1 ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
US-20230203041-A1 ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
CN-115996929-A Antagonists of adenosine A2a receptors 阿道尔克斯治疗有限公司 2023-04-21 CN disclosed
EP-4146654-A1 ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR Adorx therapeutics Limited (GB) 2023-03-15 EP disclosed
WO-2021224636-A1 ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR AdoRx Therapeutics Limited (GB) 2021-11-11 WO disclosed
WO-2021224636-A1 ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR AdoRx Therapeutics Limited (GB) 2021-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12617796-B2 Antagonists of the adenosine A2a receptor ADORA2A, ADORA2B, ADORA3 KDM4E 2597/4885ALDH1A1 1348/4885HPGD 1590/4885
US-20230203041-A1 ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR ADORA2A, ADORA1, ADORA3 KDM4E 4051/4885ALDH1A1 431/4885HPGD 1373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.